EGFR and non-small cell lung carcinoma: Two EGFR TKIs, gefitinib (ZD1839, Iressa) and erlotinib (OSI774, Tarceva), represent the first examples of molecularly targeted agents for the treatment of NSCLC and are, currently, used in the management of patients with advanced NSCLC after chemotherapy failure or in the treatment of those patients in which cancer cells harbour specific activating somatic EGFR gene mutations (Ciardiello and Tortora, 2008).